Prader-Willi syndrome is a rare genetic disease that causes poor feeding in infancy but later triggers insatiable hunger.

In a comprehensive Genomic Press Invited Expert Review, researchers from the University of Haifa have synthesized cutting-edge findings on Prader-Willi syndrome (PWS), revealing how this complex ...

HAIFA, Israel, 20 May 2025 – In a comprehensive Genomic Press Invited Expert Review, researchers from the University of Haifa have synthesized cutting-edge findings on Prader-Willi syndrome (PWS ...

In a comprehensive Genomic Press Invited Expert Review, researchers from the University of Haifa have synthesized ...

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to ...

DCCR was approved by the U.S. Food and Drug Administration (FDA) under the brand name VYKAT™ XR on March 26, 2025. Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by ...

PWS is a rare genetic disorder characterized by insatiable hunger, leading to dangerous food-seeking behaviors and severe ...

Aardvark Therapeutics, Inc. announced progress in its Phase 3 HERO trial for ARD-101, aimed at treating hyperphagia associated with Prader-Willi Syndrome, with data expected in early 2026.

The data concerns its product VYKAT XR, an extended-release tablet designed to treat hyperphagia in individuals with Prader-Willi syndrome (PWS). The study findings indicated that patients with PWS ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...